Santen Pharmaceutical Co (TSE:4536) Ending Cash Position : 円94,582 Mil (As of Mar. 2024)

View and export this data going back to 1964. Start your Free Trial

What is Santen Pharmaceutical Co Ending Cash Position?

Santen Pharmaceutical Co's Ending Cash Position for the quarter that ended in Mar. 2024 was 円94,582 Mil.

Santen Pharmaceutical Co's quarterly Ending Cash Position increased from Sep. 2023 (円64,728 Mil) to Dec. 2023 (円82,030 Mil) and increased from Dec. 2023 (円82,030 Mil) to Mar. 2024 (円94,582 Mil).

Santen Pharmaceutical Co's annual Ending Cash Position declined from Mar. 2022 (円83,014 Mil) to Mar. 2023 (円57,903 Mil) but then increased from Mar. 2023 (円57,903 Mil) to Mar. 2024 (円94,582 Mil).

Santen Pharmaceutical Co Ending Cash Position Historical Data

The historical data trend for Santen Pharmaceutical Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santen Pharmaceutical Co Ending Cash Position Chart

Santen Pharmaceutical Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Ending Cash Position

Get a 7-Day Free Trial

91,430.00

62,888.00

83,014.00

57,903.00

94,582.00

Santen Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial															57,903.00	45,510.00	64,728.00	82,030.00	94,582.00

Santen Pharmaceutical Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Santen Pharmaceutical Co's Ending Cash Position for the fiscal year that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	57903	+	36679
	=	94,582

Santen Pharmaceutical Co's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	82031	+	12551
	=	94,582

Santen Pharmaceutical Co Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Santen Pharmaceutical Co's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Santen Pharmaceutical Co (TSE:4536) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Santen Pharmaceutical Co Ltd (TSE:4536) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

SNPHY:USA SNPHF:USA SZD:Germany

Address

Grand Front Osaka Tower A, 4-20 Ofuka-cho, Kita-ku, Osaka, JPN, 530-8552

Website

http://www.santen.co.jp

Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company reports two primary operating segments: prescription ophthalmic pharmaceuticals and other. The pharmaceuticals segment includes over-the-counter pharmaceuticals, while the other segment includes medical devices. The vast majority of Santen's revenue is derived from its prescription ophthalmic pharmaceuticals segment, which manufactures and distributes prescription and OTC pharmaceuticals. Most of Santen's sales are generated in Japan, followed by other Asian countries.

Santen Pharmaceutical Co (TSE:4536) Headlines

No Headlines